Skip to main content
Equibles

CVI Investments, Inc.

Regulatory profile

From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.

Holder type
Unknown

Schedule 13D/13G stakes

Stakes of 5% or more disclosed on Schedule 13D or 13G, each on the filer's latest filing for the security. These are event-dated stakes, not the quarter-end 13F portfolio below.

Company Schedule Filed Shares % of class Status
SBFM Sunshine Biopharma Inc. 13G 23d 79,413 9.9% Current
OTLK Outlook Therapeutics, Inc. 13G 3mo 24,713,908 9.9% Current
EWAVU now EWAV East West Ave Acquisition Corp. 13G 3mo 900,000 7% Current
MBRX Moleculin Biotech, Inc. 13G 3mo 93,169 9.9% Current
CISS C3is Inc. 13G 3mo 30,529 9.9% Current
APVO Aptevo Therapeutics Inc. 13G/A 3mo 83,854 6.3% Current
BNGO Bionano Genomics, Inc. 13G/A 3mo 1,307,135 9.9% Current
CTXR Citius Pharmaceuticals, Inc. 13G/A 3mo 3,008,529 9.9% Current
ELPW Elong Power Holding Ltd. 13G/A 3mo 16,101 9.9% Current
NYXH Nyxoah SA 13G/A 3mo 11,014,861 9.9% Current
SCYX Scynexis Inc 13G/A 3mo 615,522 5.9% Current
SLDP Solid Power, Inc. 13G/A 3mo 25,218,311 9.9% Current
CALC CalciMedica, Inc. 13G 4mo 311,216 5.1% Current
AETR Aetherion Technologies Inc. 13G 4mo 1,930,712 9.9% Current
LAES SEALSQ Corp 13G/A 6mo 24,377,058 9.9% Current
PCSA Processa Pharmaceuticals, Inc. 13G/A 6mo 200,000 7% Current
SXTP 60 Degrees Pharmaceuticals, Inc. 13G/A 6mo 197,911 7% Current
BMEA Biomea Fusion, Inc. 13G/A 9mo 7,847,232 9.9% Current
DCOY Decoy Therapeutics Inc. 13G/A 9mo 59,047 9.9% Current
FSHP Flag Ship Acquisition Corp 13G 6mo 306,569 6.1% Current
PHIO Phio Pharmaceuticals Corp. 13G/A 9mo 1,194,719 9.9% Current
NA Nano Labs Ltd 13G/A 12mo 1,811,033 8.1% Current
INVZ Innoviz Technologies Ltd. 13G/A 1y 11,510,791 5.5% Current
TENX Tenax Therapeutics, Inc. 13G 2y 204,027 9.9% Unconfirmed since Feb 8, 2024

A 13D or 13G stays in force until its filer amends it and no amendment is due without a material change, so a stake with no filing in 24 months reads unconfirmed, never sold. An amendment reporting under 5% ends the filer's duty to amend, not necessarily the holding. Shares are restated onto today's split basis. Show 56 exited, below-5% or retired stakes

Portfolio style

Not measured yet. Quarters are measured from the first covered 13F quarter, once each filing window closes.

How the bands are measured

Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.

Clone Performance

Build a hypothetical price-return history from this filer's public 13F holdings.

View clone backtest

No Portfolio Data

No 13F holdings on record; this filer discloses its stakes on Schedule 13D/13G above.